Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

8.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
The Tumor Microenvironment02:17

The Tumor Microenvironment

8.2K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
8.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Cancer Vaccines01:30

Cancer Vaccines

1.4K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identifying and Addressing Barriers to Live Primary Prostate Cancer Cell Research in Veterans.

Cancer research communications·2026
Same author

Integrative Surface Antigen Profiling of KLK2 and STEAP1 in Advanced Prostate Cancer.

Molecular cancer research : MCR·2026
Same author

NCCN Guidelines® Insights: Prostate Cancer, Version 5.2026.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Development of a novel fluid removal system to increase throughput and uniformity of fluid exchange in an open microfluidic culture platform.

SLAS technology·2026
Same author

Matching Patients With Cell Surface-Targeted Clinical Trials Using Large Language Models.

JCO precision oncology·2026
Same author

Phase I multi-center clinical and biomarker study of the dual-action androgen receptor inhibitor ONCT-534.

Investigational new drugs·2026

Related Experiment Video

Updated: Apr 17, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

13.0K

Augmenting antitumor immune responses with epigenetic modifying agents.

Erika Héninger1, Timothy E G Krueger1, Joshua M Lang2

  • 1University of Wisconsin Carbone Cancer Center , Madison, WI , USA.

Frontiers in Immunology
|February 21, 2015
PubMed
Summary

Epigenetic silencing of immune genes helps tumors evade detection. Epigenetic therapies can reverse this, potentially enhancing cancer immunotherapy by restoring immune recognition and tumor cell killing.

Keywords:
antigen presentationepigeneticshistone acetylationmethylationtumor immunotherapy

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

2.0K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.2K

Related Experiment Videos

Last Updated: Apr 17, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

13.0K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

2.0K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.2K

Area of Science:

  • Oncology
  • Immunology
  • Epigenetics

Background:

  • Epigenetic silencing of immune-related genes is common in cancer.
  • This silencing impairs tumor antigen presentation and immune evasion.
  • The tumor microenvironment is further modulated by immunosuppressive cytokines, hindering anti-tumor immunity.

Purpose of the Study:

  • To explore the therapeutic potential of epigenetic modulation in cancer.
  • To investigate the reversal of tumor-induced immunosuppression via epigenetic mechanisms.
  • To highlight the combination of epigenetic and immune therapies for improved clinical outcomes.

Main Methods:

  • Review of pre-clinical studies on epigenetic modulation of immune system components.
  • Analysis of clinical studies employing epigenetic therapies in conjunction with immunotherapy.
  • Examination of epigenetic effects on antigen presentation, T-cell function, and suppressor mechanisms.

Main Results:

  • Epigenetic mechanisms can modulate antigen presentation and effector T-cell function.
  • Reversal of immunosuppression through epigenetic means can break tumor suppressor mechanisms.
  • Pre-clinical and clinical data suggest improved outcomes when combining epigenetic and immune therapies.

Conclusions:

  • Epigenetic modulation offers a promising strategy to enhance anti-tumor immunity.
  • Reinstating endogenous immune recognition and tumor lysis is achievable through epigenetic therapies.
  • Combining epigenetic therapies with immunotherapies represents a versatile approach to improve cancer treatment.